share_log

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Sees Significant Increase in Short Interest

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Sees Significant Increase in Short Interest

思維醫學(MindMed)公司(納斯達克代碼：MNMD)在空頭股數的銷量大幅增長
Defense World ·  2022/10/03 02:21

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Rating) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 963,800 shares, a growth of 13.8% from the August 31st total of 846,700 shares. Based on an average daily trading volume, of 847,500 shares, the short-interest ratio is presently 1.1 days. Currently, 0.2% of the company's shares are short sold.

思維醫學(納斯達克代碼：MNMD-GET Rating)在9月份的空頭股數業務出現了大幅增長。截至9月15日，空頭股數共有96.38萬股，較8月31日的84.67萬股增長13.8%。以日均成交量84.75萬股計算，目前短息比為1.1天。目前，該公司0.2%的股票被賣空。

Mind Medicine (MindMed) Stock Up 1.7 %

Mind Medicine(MindMed)股價上漲1.7%

Shares of NASDAQ:MNMD opened at 3.50 on Monday. Mind Medicine has a 52-week low of 2.85 and a 52-week high of 44.10. The stock has a market cap of $99.70 million, a price-to-earnings ratio of -1.30 and a beta of 1.27. The business has a 50-day moving average price of 9.44 and a 200-day moving average price of 11.63.

週一，納斯達克：MNMD的股價開盤報3.50美元。Mind Medicine的52周低點為2.85，52周高位為44.10。該股市值為9970萬美元，市盈率為-1.30倍，貝塔係數為1.27。該業務的50日移動均線價格為9.44,200日移動均線價格為11.63。

Get
到達
Mind Medicine (MindMed)
精神醫學(MindMed)
alerts:
警報：

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported -0.60 EPS for the quarter, beating analysts' consensus estimates of -0.75 by 0.15. As a group, equities analysts anticipate that Mind Medicine will post -2.51 EPS for the current fiscal year.

思維醫學(MindMed)(納斯達克代碼：MNMD-GET Rating)最近一次公佈季度收益數據是在8月11日(星期四)。該公司公佈本季度每股收益為-0.60，超出分析師一致預期的-0.75-0.15。作為一個整體，股票分析師預計Mind Medicine本財年的每股收益將達到2.51歐元。

Institutional Trading of Mind Medicine (MindMed)

精神醫學機構交易(MindMed)

A number of institutional investors and hedge funds have recently made changes to their positions in MNMD. Quantum Private Wealth LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $28,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $328,000. Laurion Capital Management LP acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $85,000. Millennium Management LLC boosted its stake in shares of Mind Medicine (MindMed) by 1,063.1% in the second quarter. Millennium Management LLC now owns 5,075,110 shares of the company's stock worth $3,249,000 after acquiring an additional 4,638,774 shares during the last quarter. Finally, LPL Financial LLC acquired a new stake in shares of Mind Medicine (MindMed) in the second quarter worth approximately $496,000. 5.10% of the stock is currently owned by hedge funds and other institutional investors.
一些機構投資者和對衝基金最近改變了他們在MNMD的頭寸。量子私人財富有限責任公司在第二季度收購了MindMed的新股份，價值約28,000美元。Cubist Systems Strategy LLC在第二季度收購了MindMed(MindMed)的新股份，價值約328,000美元。Laurion Capital Management LP在第二季度收購了Mind Medicine(MindMed)價值約8.5萬美元的新股份。千禧管理有限責任公司在第二季度將其在MindMed的股份增加了1063.1%。Millennium Management LLC在上個季度增持了4,638,774股後，現在擁有5,075,110股該公司股票，價值3,249,000美元。最後，LPL Financial LLC在第二季度收購了MindMed(MindMed)公司價值約49.6萬美元的新股份。5.10%的股票目前由對衝基金和其他機構投資者持有。

Analyst Upgrades and Downgrades

分析師升級和下調評級

A number of research firms have weighed in on MNMD. HC Wainwright increased their target price on Mind Medicine (MindMed) to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, September 21st. Cantor Fitzgerald began coverage on Mind Medicine (MindMed) in a research report on Wednesday, August 10th. They set an "overweight" rating and a $45.00 price target on the stock. Finally, Oppenheimer increased their price target on Mind Medicine (MindMed) from $3.50 to $52.00 in a research report on Tuesday, August 30th.

一些研究公司已經對MNMD發表了看法。9月21日，週三，HC Wainwright在一份研究報告中將MindMed的目標價上調至75.00美元，並給出了該股的“買入”評級。坎託·菲茨傑拉德在8月10日星期三的一份研究報告中開始報道精神醫學(MindMed)。他們為該股設定了“增持”評級和45.00美元的目標價。最後，在8月30日星期二的一份研究報告中，奧本海默將MindMed的目標價從3.50美元上調至52.00美元。

Mind Medicine (MindMed) Company Profile

Mind Medicine(MindMed)公司簡介

(Get Rating)

(獲取評級)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine(MindMed)Inc.是一家臨牀階段的生物製藥公司，開發新的產品來治療與精神病學、成癮、疼痛和神經學相關的大腦健康疾病。該公司開發了MM-120和MM-110，MM-120處於第二階段，用於治療廣泛性焦慮症和注意力缺陷多動障礙，以及治療慢性疼痛；MM-110是一種A3？4尼古丁膽鹼能受體拮抗劑，已完成治療阿片類藥物戒斷的第一階段。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Mind Medicine (MindMed) (MNMD)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • 免費獲取StockNews.com關於精神醫學的研究報告(MindMed)(MNMD)
  • 阿徹·丹尼爾斯·米德蘭：49年增長的紅利英雄
  • 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎？
  • 麥格納國際是您的汽車和電動汽車一站式庫存
  • 電動汽車電池製造商Freyr將在全球大舉擴張
  • MarketBeat：回顧一週9/26-9/30

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.

接受精神醫學(MindMed)每日新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收有關Mind Medicine(MindMed)和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論